nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—Pseudoephedrine—IL2—lung cancer	0.00836	0.353	CrCbGaD
Phenylpropanolamine—Hepatocellular injury—Erlotinib—lung cancer	0.00766	0.0172	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Crizotinib—lung cancer	0.00633	0.0142	CcSEcCtD
Phenylpropanolamine—Liver injury—Cisplatin—lung cancer	0.00589	0.0132	CcSEcCtD
Phenylpropanolamine—Vision blurred—Crizotinib—lung cancer	0.00581	0.013	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Pemetrexed—lung cancer	0.00578	0.013	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Gefitinib—lung cancer	0.00575	0.0129	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Cisplatin—lung cancer	0.00496	0.0111	CcSEcCtD
Phenylpropanolamine—Flushing—Teniposide—lung cancer	0.00487	0.0109	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Paclitaxel—lung cancer	0.00474	0.0106	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Teniposide—lung cancer	0.00469	0.0105	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Crizotinib—lung cancer	0.00449	0.0101	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Paclitaxel—lung cancer	0.00445	0.00999	CcSEcCtD
Phenylpropanolamine—Constipation—Crizotinib—lung cancer	0.0043	0.00965	CcSEcCtD
Phenylpropanolamine—Hypotension—Gefitinib—lung cancer	0.00427	0.00958	CcSEcCtD
Phenylpropanolamine—Agitation—Teniposide—lung cancer	0.0042	0.00941	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Pemetrexed—lung cancer	0.0041	0.0092	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Gefitinib—lung cancer	0.00408	0.00914	CcSEcCtD
Phenylpropanolamine—Constipation—Pemetrexed—lung cancer	0.00393	0.00882	CcSEcCtD
Phenylpropanolamine—Constipation—Gefitinib—lung cancer	0.00391	0.00876	CcSEcCtD
Phenylpropanolamine—Tranylcypromine—CYP2A6—lung cancer	0.00385	0.163	CrCbGaD
Phenylpropanolamine—Hepatocellular injury—Docetaxel—lung cancer	0.00378	0.00846	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Docetaxel—lung cancer	0.00378	0.00846	CcSEcCtD
Phenylpropanolamine—Confusional state—Teniposide—lung cancer	0.00376	0.00842	CcSEcCtD
Phenylpropanolamine—Tachycardia—Teniposide—lung cancer	0.00364	0.00815	CcSEcCtD
Phenylpropanolamine—Hypotension—Teniposide—lung cancer	0.00348	0.00781	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Erlotinib—lung cancer	0.00344	0.0077	CcSEcCtD
Phenylpropanolamine—Irritability—Cisplatin—lung cancer	0.00344	0.0077	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Pemetrexed—lung cancer	0.00339	0.0076	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Gefitinib—lung cancer	0.00337	0.00755	CcSEcCtD
Phenylpropanolamine—Dizziness—Crizotinib—lung cancer	0.00333	0.00746	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Teniposide—lung cancer	0.00332	0.00745	CcSEcCtD
Phenylpropanolamine—Vomiting—Crizotinib—lung cancer	0.0032	0.00718	CcSEcCtD
Phenylpropanolamine—Rash—Crizotinib—lung cancer	0.00317	0.00712	CcSEcCtD
Phenylpropanolamine—Dermatitis—Crizotinib—lung cancer	0.00317	0.00711	CcSEcCtD
Phenylpropanolamine—Flushing—Vinorelbine—lung cancer	0.00309	0.00692	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Teniposide—lung cancer	0.00307	0.00688	CcSEcCtD
Phenylpropanolamine—Dizziness—Pemetrexed—lung cancer	0.00304	0.00682	CcSEcCtD
Phenylpropanolamine—Ataxia—Paclitaxel—lung cancer	0.00304	0.00682	CcSEcCtD
Phenylpropanolamine—Nausea—Crizotinib—lung cancer	0.00299	0.0067	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Vinorelbine—lung cancer	0.00297	0.00666	CcSEcCtD
Phenylpropanolamine—Vomiting—Pemetrexed—lung cancer	0.00292	0.00656	CcSEcCtD
Phenylpropanolamine—Vomiting—Gefitinib—lung cancer	0.00291	0.00652	CcSEcCtD
Phenylpropanolamine—Rash—Pemetrexed—lung cancer	0.0029	0.0065	CcSEcCtD
Phenylpropanolamine—Dermatitis—Pemetrexed—lung cancer	0.0029	0.0065	CcSEcCtD
Phenylpropanolamine—Rash—Gefitinib—lung cancer	0.00288	0.00646	CcSEcCtD
Phenylpropanolamine—Dermatitis—Gefitinib—lung cancer	0.00288	0.00646	CcSEcCtD
Phenylpropanolamine—Anxiety—Erlotinib—lung cancer	0.00284	0.00637	CcSEcCtD
Phenylpropanolamine—Liver injury—Doxorubicin—lung cancer	0.0028	0.00628	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Teniposide—lung cancer	0.00275	0.00615	CcSEcCtD
Phenylpropanolamine—Tranylcypromine—CYP2E1—lung cancer	0.00274	0.115	CrCbGaD
Phenylpropanolamine—Nausea—Pemetrexed—lung cancer	0.00273	0.00613	CcSEcCtD
Phenylpropanolamine—Nausea—Gefitinib—lung cancer	0.00272	0.00609	CcSEcCtD
Phenylpropanolamine—Ataxia—Docetaxel—lung cancer	0.00258	0.00578	CcSEcCtD
Phenylpropanolamine—Flushing—Irinotecan—lung cancer	0.00255	0.00571	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Doxorubicin—lung cancer	0.00251	0.00562	CcSEcCtD
Phenylpropanolamine—Amphetamine—CYP2A6—lung cancer	0.00248	0.105	CrCbGaD
Phenylpropanolamine—Insomnia—Erlotinib—lung cancer	0.00247	0.00554	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Topotecan—lung cancer	0.00246	0.00552	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Irinotecan—lung cancer	0.00245	0.00549	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Erlotinib—lung cancer	0.00244	0.00546	CcSEcCtD
Phenylpropanolamine—Constipation—Vinblastine—lung cancer	0.00243	0.00545	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Doxorubicin—lung cancer	0.0024	0.00538	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Gemcitabine—lung cancer	0.00239	0.00535	CcSEcCtD
Phenylpropanolamine—Vomiting—Teniposide—lung cancer	0.00237	0.00531	CcSEcCtD
Phenylpropanolamine—Constipation—Topotecan—lung cancer	0.00236	0.0053	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Doxorubicin—lung cancer	0.00236	0.00528	CcSEcCtD
Phenylpropanolamine—Rash—Teniposide—lung cancer	0.00235	0.00527	CcSEcCtD
Phenylpropanolamine—Dermatitis—Teniposide—lung cancer	0.00235	0.00526	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Vinblastine—lung cancer	0.00234	0.00525	CcSEcCtD
Phenylpropanolamine—Constipation—Erlotinib—lung cancer	0.00234	0.00524	CcSEcCtD
Phenylpropanolamine—Flushing—Cisplatin—lung cancer	0.00231	0.00518	CcSEcCtD
Phenylpropanolamine—Tachycardia—Vinorelbine—lung cancer	0.00231	0.00517	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Topotecan—lung cancer	0.00228	0.0051	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Cisplatin—lung cancer	0.00222	0.00499	CcSEcCtD
Phenylpropanolamine—Nausea—Teniposide—lung cancer	0.00221	0.00496	CcSEcCtD
Phenylpropanolamine—Benzyl alcohol—CYP2E1—lung cancer	0.00221	0.0933	CrCbGaD
Phenylpropanolamine—Hypotension—Vinorelbine—lung cancer	0.00221	0.00495	CcSEcCtD
Phenylpropanolamine—Benzyl alcohol—CYP1A1—lung cancer	0.00218	0.092	CrCbGaD
Phenylpropanolamine—Flushing—Etoposide—lung cancer	0.00212	0.00475	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Vinorelbine—lung cancer	0.00211	0.00472	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Vinblastine—lung cancer	0.00209	0.0047	CcSEcCtD
Phenylpropanolamine—Flushing—Paclitaxel—lung cancer	0.00208	0.00465	CcSEcCtD
Phenylpropanolamine—Vision blurred—Cisplatin—lung cancer	0.00204	0.00458	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Topotecan—lung cancer	0.00203	0.00456	CcSEcCtD
Phenylpropanolamine—Tremor—Cisplatin—lung cancer	0.00203	0.00455	CcSEcCtD
Phenylpropanolamine—Constipation—Vinorelbine—lung cancer	0.00202	0.00453	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Paclitaxel—lung cancer	0.002	0.00448	CcSEcCtD
Phenylpropanolamine—Confusional state—Irinotecan—lung cancer	0.00196	0.0044	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Vinorelbine—lung cancer	0.00195	0.00436	CcSEcCtD
Phenylpropanolamine—Tension—Paclitaxel—lung cancer	0.00191	0.00428	CcSEcCtD
Phenylpropanolamine—Nervousness—Paclitaxel—lung cancer	0.00189	0.00424	CcSEcCtD
Phenylpropanolamine—Irritability—Methotrexate—lung cancer	0.00189	0.00423	CcSEcCtD
Phenylpropanolamine—Dizziness—Vinblastine—lung cancer	0.00188	0.00421	CcSEcCtD
Phenylpropanolamine—Phenelzine—CYP2E1—lung cancer	0.00187	0.0789	CrCbGaD
Phenylpropanolamine—Ataxia—Methotrexate—lung cancer	0.00186	0.00416	CcSEcCtD
Phenylpropanolamine—Anxiety—Cisplatin—lung cancer	0.00184	0.00412	CcSEcCtD
Phenylpropanolamine—Vision blurred—Paclitaxel—lung cancer	0.00184	0.00411	CcSEcCtD
Phenylpropanolamine—Dizziness—Topotecan—lung cancer	0.00183	0.00409	CcSEcCtD
Phenylpropanolamine—Tremor—Paclitaxel—lung cancer	0.00182	0.00409	CcSEcCtD
Phenylpropanolamine—Hypotension—Irinotecan—lung cancer	0.00182	0.00408	CcSEcCtD
Phenylpropanolamine—Vomiting—Vinblastine—lung cancer	0.00181	0.00405	CcSEcCtD
Phenylpropanolamine—Dizziness—Erlotinib—lung cancer	0.00181	0.00405	CcSEcCtD
Phenylpropanolamine—Agitation—Paclitaxel—lung cancer	0.00179	0.00401	CcSEcCtD
Phenylpropanolamine—Hypotension—Gemcitabine—lung cancer	0.00177	0.00398	CcSEcCtD
Phenylpropanolamine—Insomnia—Irinotecan—lung cancer	0.00176	0.00395	CcSEcCtD
Phenylpropanolamine—Flushing—Docetaxel—lung cancer	0.00176	0.00394	CcSEcCtD
Phenylpropanolamine—Vomiting—Topotecan—lung cancer	0.00176	0.00394	CcSEcCtD
Phenylpropanolamine—Rash—Topotecan—lung cancer	0.00174	0.0039	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Vinorelbine—lung cancer	0.00174	0.0039	CcSEcCtD
Phenylpropanolamine—Dermatitis—Topotecan—lung cancer	0.00174	0.0039	CcSEcCtD
Phenylpropanolamine—Vomiting—Erlotinib—lung cancer	0.00174	0.0039	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Irinotecan—lung cancer	0.00174	0.00389	CcSEcCtD
Phenylpropanolamine—Somnolence—Irinotecan—lung cancer	0.00173	0.00388	CcSEcCtD
Phenylpropanolamine—Tachycardia—Cisplatin—lung cancer	0.00173	0.00387	CcSEcCtD
Phenylpropanolamine—Rash—Erlotinib—lung cancer	0.00172	0.00386	CcSEcCtD
Phenylpropanolamine—Dermatitis—Erlotinib—lung cancer	0.00172	0.00386	CcSEcCtD
Phenylpropanolamine—Insomnia—Gemcitabine—lung cancer	0.00172	0.00385	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Docetaxel—lung cancer	0.00169	0.0038	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Gemcitabine—lung cancer	0.00169	0.00379	CcSEcCtD
Phenylpropanolamine—Nausea—Vinblastine—lung cancer	0.00169	0.00379	CcSEcCtD
Phenylpropanolamine—Somnolence—Gemcitabine—lung cancer	0.00169	0.00378	CcSEcCtD
Phenylpropanolamine—Constipation—Irinotecan—lung cancer	0.00167	0.00374	CcSEcCtD
Phenylpropanolamine—Hypotension—Cisplatin—lung cancer	0.00165	0.00371	CcSEcCtD
Phenylpropanolamine—Anxiety—Paclitaxel—lung cancer	0.00165	0.0037	CcSEcCtD
Phenylpropanolamine—Nausea—Topotecan—lung cancer	0.00164	0.00368	CcSEcCtD
Phenylpropanolamine—Confusional state—Etoposide—lung cancer	0.00163	0.00366	CcSEcCtD
Phenylpropanolamine—Constipation—Gemcitabine—lung cancer	0.00162	0.00364	CcSEcCtD
Phenylpropanolamine—Nausea—Erlotinib—lung cancer	0.00162	0.00364	CcSEcCtD
Phenylpropanolamine—Ataxia—Doxorubicin—lung cancer	0.00161	0.00361	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Irinotecan—lung cancer	0.00161	0.0036	CcSEcCtD
Phenylpropanolamine—Confusional state—Paclitaxel—lung cancer	0.0016	0.00359	CcSEcCtD
Phenylpropanolamine—Tachycardia—Etoposide—lung cancer	0.00158	0.00355	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Cisplatin—lung cancer	0.00158	0.00354	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Gemcitabine—lung cancer	0.00156	0.00351	CcSEcCtD
Phenylpropanolamine—Dizziness—Vinorelbine—lung cancer	0.00156	0.0035	CcSEcCtD
Phenylpropanolamine—Tachycardia—Paclitaxel—lung cancer	0.00155	0.00348	CcSEcCtD
Phenylpropanolamine—Drowsiness—Methotrexate—lung cancer	0.00152	0.00341	CcSEcCtD
Phenylpropanolamine—Hypotension—Etoposide—lung cancer	0.00151	0.0034	CcSEcCtD
Phenylpropanolamine—Vomiting—Vinorelbine—lung cancer	0.0015	0.00337	CcSEcCtD
Phenylpropanolamine—Rash—Vinorelbine—lung cancer	0.00149	0.00334	CcSEcCtD
Phenylpropanolamine—Dermatitis—Vinorelbine—lung cancer	0.00149	0.00334	CcSEcCtD
Phenylpropanolamine—Hypotension—Paclitaxel—lung cancer	0.00148	0.00333	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Cisplatin—lung cancer	0.00146	0.00327	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Etoposide—lung cancer	0.00144	0.00324	CcSEcCtD
Phenylpropanolamine—Somnolence—Etoposide—lung cancer	0.00144	0.00323	CcSEcCtD
Phenylpropanolamine—Insomnia—Paclitaxel—lung cancer	0.00144	0.00322	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Irinotecan—lung cancer	0.00144	0.00322	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Paclitaxel—lung cancer	0.00142	0.00318	CcSEcCtD
Phenylpropanolamine—Somnolence—Paclitaxel—lung cancer	0.00141	0.00317	CcSEcCtD
Phenylpropanolamine—Nausea—Vinorelbine—lung cancer	0.0014	0.00315	CcSEcCtD
Phenylpropanolamine—Constipation—Etoposide—lung cancer	0.00139	0.00311	CcSEcCtD
Phenylpropanolamine—Constipation—Paclitaxel—lung cancer	0.00136	0.00305	CcSEcCtD
Phenylpropanolamine—Confusional state—Docetaxel—lung cancer	0.00136	0.00304	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Etoposide—lung cancer	0.00134	0.00299	CcSEcCtD
Phenylpropanolamine—Drowsiness—Doxorubicin—lung cancer	0.00132	0.00296	CcSEcCtD
Phenylpropanolamine—Tachycardia—Docetaxel—lung cancer	0.00131	0.00295	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Paclitaxel—lung cancer	0.00131	0.00294	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Cisplatin—lung cancer	0.0013	0.00292	CcSEcCtD
Phenylpropanolamine—Dizziness—Irinotecan—lung cancer	0.00129	0.00289	CcSEcCtD
Phenylpropanolamine—Hypotension—Docetaxel—lung cancer	0.00126	0.00282	CcSEcCtD
Phenylpropanolamine—Vomiting—Irinotecan—lung cancer	0.00124	0.00278	CcSEcCtD
Phenylpropanolamine—Rash—Irinotecan—lung cancer	0.00123	0.00275	CcSEcCtD
Phenylpropanolamine—Dermatitis—Irinotecan—lung cancer	0.00123	0.00275	CcSEcCtD
Phenylpropanolamine—Insomnia—Docetaxel—lung cancer	0.00122	0.00273	CcSEcCtD
Phenylpropanolamine—Vomiting—Gemcitabine—lung cancer	0.00121	0.00271	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Docetaxel—lung cancer	0.0012	0.00269	CcSEcCtD
Phenylpropanolamine—Somnolence—Docetaxel—lung cancer	0.0012	0.00268	CcSEcCtD
Phenylpropanolamine—Rash—Gemcitabine—lung cancer	0.0012	0.00268	CcSEcCtD
Phenylpropanolamine—Dermatitis—Gemcitabine—lung cancer	0.0012	0.00268	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Etoposide—lung cancer	0.00119	0.00268	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Paclitaxel—lung cancer	0.00117	0.00262	CcSEcCtD
Phenylpropanolamine—Nausea—Irinotecan—lung cancer	0.00116	0.00259	CcSEcCtD
Phenylpropanolamine—Constipation—Docetaxel—lung cancer	0.00115	0.00258	CcSEcCtD
Phenylpropanolamine—Nausea—Gemcitabine—lung cancer	0.00113	0.00253	CcSEcCtD
Phenylpropanolamine—Vomiting—Cisplatin—lung cancer	0.00112	0.00252	CcSEcCtD
Phenylpropanolamine—Vision blurred—Methotrexate—lung cancer	0.00112	0.00251	CcSEcCtD
Phenylpropanolamine—Rash—Cisplatin—lung cancer	0.00112	0.0025	CcSEcCtD
Phenylpropanolamine—Dermatitis—Cisplatin—lung cancer	0.00111	0.0025	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Docetaxel—lung cancer	0.00111	0.00249	CcSEcCtD
Phenylpropanolamine—Flushing—Doxorubicin—lung cancer	0.0011	0.00246	CcSEcCtD
Phenylpropanolamine—Dizziness—Etoposide—lung cancer	0.00107	0.0024	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Doxorubicin—lung cancer	0.00106	0.00237	CcSEcCtD
Phenylpropanolamine—Dizziness—Paclitaxel—lung cancer	0.00105	0.00236	CcSEcCtD
Phenylpropanolamine—Nausea—Cisplatin—lung cancer	0.00105	0.00236	CcSEcCtD
Phenylpropanolamine—Vomiting—Etoposide—lung cancer	0.00103	0.00231	CcSEcCtD
Phenylpropanolamine—Rash—Etoposide—lung cancer	0.00102	0.00229	CcSEcCtD
Phenylpropanolamine—Dermatitis—Etoposide—lung cancer	0.00102	0.00229	CcSEcCtD
Phenylpropanolamine—Tension—Doxorubicin—lung cancer	0.00101	0.00227	CcSEcCtD
Phenylpropanolamine—Vomiting—Paclitaxel—lung cancer	0.00101	0.00227	CcSEcCtD
Phenylpropanolamine—Rash—Paclitaxel—lung cancer	0.001	0.00225	CcSEcCtD
Phenylpropanolamine—Dermatitis—Paclitaxel—lung cancer	0.001	0.00224	CcSEcCtD
Phenylpropanolamine—Nervousness—Doxorubicin—lung cancer	0.001	0.00224	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Docetaxel—lung cancer	0.000992	0.00222	CcSEcCtD
Phenylpropanolamine—Confusional state—Methotrexate—lung cancer	0.000979	0.00219	CcSEcCtD
Phenylpropanolamine—Vision blurred—Doxorubicin—lung cancer	0.000971	0.00218	CcSEcCtD
Phenylpropanolamine—Nausea—Etoposide—lung cancer	0.000963	0.00216	CcSEcCtD
Phenylpropanolamine—Agitation—Doxorubicin—lung cancer	0.000947	0.00212	CcSEcCtD
Phenylpropanolamine—Nausea—Paclitaxel—lung cancer	0.000944	0.00212	CcSEcCtD
Phenylpropanolamine—Hypotension—Methotrexate—lung cancer	0.000907	0.00203	CcSEcCtD
Phenylpropanolamine—Dizziness—Docetaxel—lung cancer	0.000891	0.002	CcSEcCtD
Phenylpropanolamine—Insomnia—Methotrexate—lung cancer	0.000878	0.00197	CcSEcCtD
Phenylpropanolamine—Anxiety—Doxorubicin—lung cancer	0.000874	0.00196	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Methotrexate—lung cancer	0.000866	0.00194	CcSEcCtD
Phenylpropanolamine—Somnolence—Methotrexate—lung cancer	0.000863	0.00193	CcSEcCtD
Phenylpropanolamine—Vomiting—Docetaxel—lung cancer	0.000856	0.00192	CcSEcCtD
Phenylpropanolamine—Rash—Docetaxel—lung cancer	0.000849	0.0019	CcSEcCtD
Phenylpropanolamine—Dermatitis—Docetaxel—lung cancer	0.000849	0.0019	CcSEcCtD
Phenylpropanolamine—Confusional state—Doxorubicin—lung cancer	0.000848	0.0019	CcSEcCtD
Phenylpropanolamine—Tachycardia—Doxorubicin—lung cancer	0.00082	0.00184	CcSEcCtD
Phenylpropanolamine—Nausea—Docetaxel—lung cancer	0.0008	0.00179	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Methotrexate—lung cancer	0.0008	0.00179	CcSEcCtD
Phenylpropanolamine—Hypotension—Doxorubicin—lung cancer	0.000786	0.00176	CcSEcCtD
Phenylpropanolamine—Insomnia—Doxorubicin—lung cancer	0.00076	0.0017	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Doxorubicin—lung cancer	0.000749	0.00168	CcSEcCtD
Phenylpropanolamine—Somnolence—Doxorubicin—lung cancer	0.000747	0.00168	CcSEcCtD
Phenylpropanolamine—Constipation—Doxorubicin—lung cancer	0.000719	0.00161	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Methotrexate—lung cancer	0.000715	0.0016	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Doxorubicin—lung cancer	0.000693	0.00155	CcSEcCtD
Phenylpropanolamine—Dizziness—Methotrexate—lung cancer	0.000642	0.00144	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Doxorubicin—lung cancer	0.000619	0.00139	CcSEcCtD
Phenylpropanolamine—Vomiting—Methotrexate—lung cancer	0.000617	0.00138	CcSEcCtD
Phenylpropanolamine—Rash—Methotrexate—lung cancer	0.000612	0.00137	CcSEcCtD
Phenylpropanolamine—Dermatitis—Methotrexate—lung cancer	0.000612	0.00137	CcSEcCtD
Phenylpropanolamine—Nausea—Methotrexate—lung cancer	0.000577	0.00129	CcSEcCtD
Phenylpropanolamine—Dizziness—Doxorubicin—lung cancer	0.000556	0.00125	CcSEcCtD
Phenylpropanolamine—Vomiting—Doxorubicin—lung cancer	0.000534	0.0012	CcSEcCtD
Phenylpropanolamine—Rash—Doxorubicin—lung cancer	0.00053	0.00119	CcSEcCtD
Phenylpropanolamine—Dermatitis—Doxorubicin—lung cancer	0.00053	0.00119	CcSEcCtD
Phenylpropanolamine—Nausea—Doxorubicin—lung cancer	0.000499	0.00112	CcSEcCtD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CG—lung cancer	5.25e-05	9.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL2—lung cancer	5.23e-05	9.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TERT—lung cancer	5.21e-05	9.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—EGFR—lung cancer	5.21e-05	9.82e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PTEN—lung cancer	5.21e-05	9.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOA1—lung cancer	5.18e-05	9.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAP2K1—lung cancer	5.17e-05	9.75e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP2E1—lung cancer	5.15e-05	9.72e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—PIK3CA—lung cancer	5.14e-05	9.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CD—lung cancer	5.14e-05	9.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KDR—lung cancer	5.13e-05	9.68e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MDM2—lung cancer	5.12e-05	9.66e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—RAF1—lung cancer	5.1e-05	9.62e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NQO1—lung cancer	5.1e-05	9.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—PIK3CA—lung cancer	5.09e-05	9.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—FGFR1—lung cancer	5.06e-05	9.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAP2K1—lung cancer	5.06e-05	9.54e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ERBB2—lung cancer	5.05e-05	9.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—KRAS—lung cancer	5.03e-05	9.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CD—lung cancer	5.03e-05	9.48e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—POMC—lung cancer	5e-05	9.43e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	4.99e-05	9.41e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HIF1A—lung cancer	4.99e-05	9.41e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CB—lung cancer	4.98e-05	9.39e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MTOR—lung cancer	4.98e-05	9.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—PIK3CA—lung cancer	4.98e-05	9.39e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—EP300—lung cancer	4.97e-05	9.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—AKT1—lung cancer	4.95e-05	9.33e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	4.95e-05	9.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—KRAS—lung cancer	4.92e-05	9.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CREBBP—lung cancer	4.87e-05	9.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOA1—lung cancer	4.81e-05	9.08e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CXCL8—lung cancer	4.79e-05	9.03e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KDR—lung cancer	4.77e-05	8.99e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—HRAS—lung cancer	4.76e-05	8.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APC—lung cancer	4.73e-05	8.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CG—lung cancer	4.73e-05	8.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KIT—lung cancer	4.73e-05	8.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—NRAS—lung cancer	4.73e-05	8.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EGF—lung cancer	4.67e-05	8.82e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—AKT1—lung cancer	4.62e-05	8.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PIK3CA—lung cancer	4.62e-05	8.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CD—lung cancer	4.62e-05	8.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MDM2—lung cancer	4.6e-05	8.68e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—STK11—lung cancer	4.59e-05	8.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—RAF1—lung cancer	4.59e-05	8.65e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CASP3—lung cancer	4.58e-05	8.64e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL2—lung cancer	4.57e-05	8.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ALB—lung cancer	4.56e-05	8.6e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL6—lung cancer	4.55e-05	8.58e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ERBB2—lung cancer	4.54e-05	8.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—MAPK3—lung cancer	4.53e-05	8.54e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PIK3CA—lung cancer	4.52e-05	8.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MDM2—lung cancer	4.5e-05	8.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—POMC—lung cancer	4.5e-05	8.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—RAF1—lung cancer	4.49e-05	8.46e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MTOR—lung cancer	4.48e-05	8.45e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CB—lung cancer	4.48e-05	8.45e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCND1—lung cancer	4.46e-05	8.41e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—JUN—lung cancer	4.45e-05	8.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—BRAF—lung cancer	4.44e-05	8.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ERBB2—lung cancer	4.44e-05	8.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KIT—lung cancer	4.39e-05	8.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CG—lung cancer	4.39e-05	8.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APC—lung cancer	4.39e-05	8.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—NRAS—lung cancer	4.39e-05	8.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6R—lung cancer	4.39e-05	8.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CREBBP—lung cancer	4.38e-05	8.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CB—lung cancer	4.38e-05	8.26e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MTOR—lung cancer	4.38e-05	8.26e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EGF—lung cancer	4.34e-05	8.19e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MMP9—lung cancer	4.33e-05	8.17e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CDKN1A—lung cancer	4.31e-05	8.14e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	4.31e-05	8.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—EGFR—lung cancer	4.31e-05	8.12e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTEN—lung cancer	4.3e-05	8.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CXCL8—lung cancer	4.3e-05	8.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HRAS—lung cancer	4.28e-05	8.06e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTP1—lung cancer	4.25e-05	8.02e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CXCL8—lung cancer	4.21e-05	7.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—MAPK3—lung cancer	4.21e-05	7.94e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—AKT1—lung cancer	4.2e-05	7.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAP2K1—lung cancer	4.18e-05	7.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HRAS—lung cancer	4.18e-05	7.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—POMC—lung cancer	4.18e-05	7.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—AKT1—lung cancer	4.16e-05	7.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CD—lung cancer	4.16e-05	7.84e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CAT—lung cancer	4.14e-05	7.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—BRAF—lung cancer	4.13e-05	7.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CASP3—lung cancer	4.12e-05	7.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—PIK3CA—lung cancer	4.12e-05	7.77e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	4.11e-05	7.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL2—lung cancer	4.11e-05	7.76e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EP300—lung cancer	4.1e-05	7.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL6—lung cancer	4.09e-05	7.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6R—lung cancer	4.08e-05	7.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CREBBP—lung cancer	4.07e-05	7.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—KRAS—lung cancer	4.07e-05	7.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—AKT1—lung cancer	4.07e-05	7.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CASP3—lung cancer	4.03e-05	7.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CB—lung cancer	4.03e-05	7.59e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ABCB1—lung cancer	4.02e-05	7.59e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL2—lung cancer	4.02e-05	7.59e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCND1—lung cancer	4.01e-05	7.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL6—lung cancer	4e-05	7.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—EGFR—lung cancer	4e-05	7.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—JUN—lung cancer	4e-05	7.54e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SRC—lung cancer	3.99e-05	7.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTGS2—lung cancer	3.99e-05	7.52e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TYMS—lung cancer	3.95e-05	7.45e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCND1—lung cancer	3.92e-05	7.4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—JUN—lung cancer	3.91e-05	7.38e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTM1—lung cancer	3.91e-05	7.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MMP9—lung cancer	3.89e-05	7.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAP2K1—lung cancer	3.89e-05	7.33e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VEGFA—lung cancer	3.89e-05	7.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CDKN1A—lung cancer	3.88e-05	7.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTEN—lung cancer	3.87e-05	7.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CD—lung cancer	3.86e-05	7.28e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—STAT3—lung cancer	3.85e-05	7.26e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NRAS—lung cancer	3.84e-05	7.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PIK3CA—lung cancer	3.83e-05	7.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MMP9—lung cancer	3.81e-05	7.18e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CDKN1A—lung cancer	3.79e-05	7.15e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTEN—lung cancer	3.79e-05	7.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—KRAS—lung cancer	3.78e-05	7.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—AKT1—lung cancer	3.78e-05	7.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PIK3CA—lung cancer	3.74e-05	7.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MDM2—lung cancer	3.72e-05	7.02e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—RAF1—lung cancer	3.71e-05	7e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP1A1—lung cancer	3.7e-05	6.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—AKT1—lung cancer	3.69e-05	6.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EP300—lung cancer	3.69e-05	6.96e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MAPK3—lung cancer	3.68e-05	6.94e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PIK3CA—lung cancer	3.67e-05	6.93e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ERCC2—lung cancer	3.67e-05	6.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ERBB2—lung cancer	3.67e-05	6.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MTOR—lung cancer	3.62e-05	6.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CB—lung cancer	3.62e-05	6.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EP300—lung cancer	3.61e-05	6.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SRC—lung cancer	3.59e-05	6.77e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MYC—lung cancer	3.58e-05	6.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SRC—lung cancer	3.51e-05	6.62e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EGFR—lung cancer	3.5e-05	6.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VEGFA—lung cancer	3.5e-05	6.59e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CXCL8—lung cancer	3.48e-05	6.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTEN—lung cancer	3.48e-05	6.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	3.47e-05	6.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—STAT3—lung cancer	3.46e-05	6.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MDM2—lung cancer	3.46e-05	6.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HRAS—lung cancer	3.46e-05	6.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NRAS—lung cancer	3.45e-05	6.51e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RAF1—lung cancer	3.45e-05	6.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VEGFA—lung cancer	3.42e-05	6.45e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ERBB2—lung cancer	3.41e-05	6.43e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—STAT3—lung cancer	3.39e-05	6.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NRAS—lung cancer	3.38e-05	6.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MTOR—lung cancer	3.37e-05	6.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	3.37e-05	6.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—AKT1—lung cancer	3.36e-05	6.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CASP3—lung cancer	3.33e-05	6.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL2—lung cancer	3.33e-05	6.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—EP300—lung cancer	3.32e-05	6.26e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL6—lung cancer	3.31e-05	6.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAPK3—lung cancer	3.31e-05	6.24e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—KRAS—lung cancer	3.31e-05	6.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCND1—lung cancer	3.24e-05	6.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—JUN—lung cancer	3.24e-05	6.1e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CXCL8—lung cancer	3.24e-05	6.1e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAPK3—lung cancer	3.23e-05	6.1e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MYC—lung cancer	3.22e-05	6.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HRAS—lung cancer	3.21e-05	6.06e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOA1—lung cancer	3.18e-05	5.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MMP9—lung cancer	3.15e-05	5.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MYC—lung cancer	3.15e-05	5.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EGFR—lung cancer	3.15e-05	5.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	3.14e-05	5.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTEN—lung cancer	3.13e-05	5.9e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	3.13e-05	5.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CASP3—lung cancer	3.1e-05	5.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL2—lung cancer	3.09e-05	5.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EGFR—lung cancer	3.08e-05	5.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL6—lung cancer	3.08e-05	5.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—AKT1—lung cancer	3.05e-05	5.76e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.04e-05	5.74e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CA—lung cancer	3.04e-05	5.73e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCND1—lung cancer	3.01e-05	5.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—JUN—lung cancer	3.01e-05	5.67e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—AKT1—lung cancer	3e-05	5.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EP300—lung cancer	2.99e-05	5.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—KRAS—lung cancer	2.97e-05	5.6e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TP53—lung cancer	2.94e-05	5.54e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MMP9—lung cancer	2.93e-05	5.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	2.92e-05	5.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTEN—lung cancer	2.91e-05	5.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—KRAS—lung cancer	2.91e-05	5.48e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SRC—lung cancer	2.9e-05	5.48e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CG—lung cancer	2.9e-05	5.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AKT1—lung cancer	2.84e-05	5.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VEGFA—lung cancer	2.83e-05	5.33e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HRAS—lung cancer	2.81e-05	5.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—STAT3—lung cancer	2.8e-05	5.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NRAS—lung cancer	2.79e-05	5.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EP300—lung cancer	2.77e-05	5.23e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—POMC—lung cancer	2.76e-05	5.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CA—lung cancer	2.73e-05	5.15e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SRC—lung cancer	2.7e-05	5.09e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CREBBP—lung cancer	2.69e-05	5.07e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL6—lung cancer	2.69e-05	5.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAPK3—lung cancer	2.68e-05	5.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CA—lung cancer	2.67e-05	5.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TP53—lung cancer	2.64e-05	4.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VEGFA—lung cancer	2.63e-05	4.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MYC—lung cancer	2.6e-05	4.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—STAT3—lung cancer	2.6e-05	4.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NRAS—lung cancer	2.6e-05	4.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TP53—lung cancer	2.58e-05	4.87e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CD—lung cancer	2.55e-05	4.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EGFR—lung cancer	2.55e-05	4.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HRAS—lung cancer	2.53e-05	4.76e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ALB—lung cancer	2.52e-05	4.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAPK3—lung cancer	2.49e-05	4.69e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AKT1—lung cancer	2.48e-05	4.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HRAS—lung cancer	2.47e-05	4.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CA—lung cancer	2.45e-05	4.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MYC—lung cancer	2.42e-05	4.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6—lung cancer	2.42e-05	4.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KRAS—lung cancer	2.4e-05	4.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6—lung cancer	2.36e-05	4.46e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EGFR—lung cancer	2.36e-05	4.46e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KRAS—lung cancer	2.23e-05	4.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AKT1—lung cancer	2.23e-05	4.21e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CB—lung cancer	2.22e-05	4.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	2.21e-05	4.17e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTGS2—lung cancer	2.2e-05	4.15e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AKT1—lung cancer	2.18e-05	4.11e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TP53—lung cancer	2.14e-05	4.03e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	2.05e-05	3.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HRAS—lung cancer	2.04e-05	3.85e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AKT1—lung cancer	2.01e-05	3.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TP53—lung cancer	1.99e-05	3.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6—lung cancer	1.96e-05	3.69e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTEN—lung cancer	1.92e-05	3.62e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HRAS—lung cancer	1.9e-05	3.58e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—EP300—lung cancer	1.83e-05	3.45e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6—lung cancer	1.82e-05	3.43e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT1—lung cancer	1.8e-05	3.4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT1—lung cancer	1.68e-05	3.16e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CA—lung cancer	1.35e-05	2.56e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AKT1—lung cancer	1.11e-05	2.09e-05	CbGpPWpGaD
